Skip to main content
    B

    Biogen Inc (BIIB)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $251.65
    -1.75 (-0.69%)

    Market Cap: $37.46B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Biogen Inc (BIIB) Financials: Revenue, Profit and Cash Flow

    Updated Oct 28, 2026. Financial statements from company filings, amounts in US dollars.

    Biogen reported revenue of $9.89B for the fiscal year ended Dec 31, 2025, up 2.2% from the year before. That year, net income was $1.29B with a net margin of 13.1%, operating cash flow was $2.20B and free cash flow was $2.05B. The quarter ended Sep 30, 2026 had revenue of $2.80B and net income of -$20.60M.

    Revenue and Margins

    The operating margin was 15.7% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue fell from $11.45B, a compound annual decline of 1.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$9.89B+2.2%75.7%15.7%13.1%
    Dec 2024$9.68B-1.6%76.1%19.7%16.9%
    Dec 2023$9.84B-3.3%74.2%13.2%11.8%
    Dec 2022$10.17B-7.4%77.6%34.2%29.1%
    Dec 2021$10.98B-18.3%80.8%25.9%15.7%
    Dec 2020$13.44B-6.5%86.6%33.8%30.2%
    Dec 2019$14.38B+6.9%86.4%49.0%41.0%
    Dec 2018$13.45B+9.6%86.5%43.8%33.3%
    Dec 2017$12.27B+7.2%86.7%43.6%21.8%
    Dec 2016$11.45BN/A87.1%45.0%32.3%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income fell 20.9% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$9.89B$9.68B$9.84B$10.17B$10.98B$13.44B$14.38B$13.45B$12.27B$11.45B
    Cost of revenue$2.40B$2.31B$2.53B$2.28B$2.11B$1.81B$1.96B$1.82B$1.63B$1.48B
    Gross profit$7.49B$7.37B$7.30B$7.90B$8.87B$11.64B$12.42B$11.64B$10.64B$9.97B
    Research and development$2.25B$2.04B$2.46B$2.23B$2.52B$4.07B$2.28B$2.71B$2.37B$1.97B
    Operating income$1.56B$1.91B$1.30B$3.48B$2.84B$4.55B$7.04B$5.89B$5.35B$5.15B
    Net income$1.29B$1.63B$1.16B$2.96B$1.73B$4.06B$5.89B$4.47B$2.67B$3.70B
    EBITDA$2.58B$2.81B$1.82B$4.11BN/A$5.50B$7.59B$6.55B$6.21B$5.62B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$2.80B$2.74B$2.48B$2.28B$2.53B$2.65B$2.43B$2.45B$2.47B$2.46B$2.29B$2.39B
    Gross profit$2.06B$1.96B$1.82B$1.78B$1.86B$2.04B$1.80B$1.87B$1.83B$1.92B$1.75B$1.77B
    Operating income-$9.00M$132.40M$377.70M-$69.20M$557.30M$757.20M$311.20M$291.50M$451.00M$698.70M$464.80M$291.60M
    Net income-$20.60M$97.50M$319.50M-$62.10M$466.50M$648.00M$240.50M$266.70M$388.50M$583.60M$393.40M$248.90M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $6.29B exceeded cash and equivalents by $3.28B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$29.44B$28.05B$26.84B$24.55B$23.88B$24.62B$27.23B$25.29B$23.65B$22.88B
    Current assets$8.97B$7.46B$6.86B$9.79B$7.86B$6.89B$8.38B$7.64B$7.87B$8.73B
    Cash and equivalents$3.01B$2.38B$1.05B$3.42B$2.26B$1.33B$2.91B$1.22B$1.57B$2.33B
    Total liabilities$11.18B$11.33B$12.05B$11.17B$12.92B$13.93B$13.90B$12.26B$11.05B$10.75B
    Short-term debt$0$1.75B$150.00M$0$999.10M$0$1.50B$0$3.20M$4.70M
    Long-term debt$6.29B$4.55B$6.79B$6.28B$6.27B$7.43B$4.46B$5.94B$5.93B$6.51B
    Shareholder equity$18.26B$16.72B$14.80B$13.40B$10.90B$10.70B$13.34B$13.04B$12.61B$12.14B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$32.05B$32.09B$29.48B$29.44B$29.21B$28.33B$28.03B$28.05B$28.31B$26.80B$26.57B$26.84B
    Total liabilities$13.13B$13.24B$10.83B$11.18B$11.00B$10.70B$11.05B$11.33B$11.95B$10.91B$11.35B$12.05B
    Cash and equivalents$1.30B$1.28B$3.38B$3.01B$3.86B$2.76B$2.60B$2.38B$1.70B$1.91B$1.07B$1.05B
    Shareholder equity$18.92B$18.85B$18.65B$18.26B$18.21B$17.63B$16.98B$16.72B$16.36B$15.89B$15.21B$14.80B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 93.2% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$2.20B$2.88B$1.55B$1.38B$3.64B$4.23B$7.08B$6.19B$4.55B$4.59B
    Capital expenditures$153.80M$153.70M$277.00M$240.30M$258.10M$424.80M$814.50M$2.27B$2.07B$1.82B
    Free cash flow$2.05B$2.72B$1.27B$1.14B$3.38B$3.81B$6.26B$3.92B$2.48B$2.77B
    Dividends paid$0$0$12.30M$12.40M$94.40M$71.00M$4.30M$36.40M$436.80M$0
    Share repurchasesN/AN/AN/A$750.00M$1.80B$6.68B$5.87B$4.35B$1.37B$1.00B
    Investing cash flow-$1.37B-$799.20M-$4.10B$1.58B-$563.70M-$608.60M$470.50M-$2.05B-$2.96B-$2.48B
    Financing cash flow-$301.90M-$683.50M$149.30M-$1.75B-$2.09B-$5.27B-$5.86B-$4.47B-$2.38B-$1.05B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$640.80M$448.90M$645.50M$511.90M$1.27B$160.90M$259.30M$760.90M$935.60M$625.80M$553.20M$12.50M
    Capital expenditures$40.40M$40.90M$51.20M$43.90M$46.20M$26.60M$37.10M$39.30M$35.00M$33.50M$45.90M$65.20M
    Free cash flow$600.40M$408.00M$594.30M$468.00M$1.23B$134.30M$222.20M$721.60M$900.60M$592.30M$507.30M-$52.70M
    Last 12 quarters

    Frequently Asked Questions About BIIB

    What is Biogen's annual revenue?

    Biogen reported revenue of $9.89B for the fiscal year ended Dec 31, 2025.

    How fast is Biogen's revenue growing?

    Revenue was up 2.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -0.9%.

    Is Biogen profitable?

    Yes. Biogen reported net income of $1.29B for the fiscal year ended Dec 31, 2025, with a net margin of 13.1%.

    How much free cash flow does BIIB generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $2.20B minus capital expenditures of $153.80M produced free cash flow of $2.05B.

    How much debt does Biogen have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $6.29B, short-term debt of $0 and cash and equivalents of $3.01B.